PETACH TIKVA, Israel, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Macrocure Ltd. (Nasdaq:MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, was spotlighted in five news outlets: MedCity News, published on November 12; Physicians News Digest and InformationAboutDiabetes, both published on December 2; Battle Diabetes, published on December 3; and Ostomy Wound Management published on December 9.
The MedCity News article, titled, "Israeli wound care serum made up of live white blood cells headed stateside," notes unique features of CureXcell™, clinical trial results from studies in Israel and the regulatory pathway in the United States. To read the MedCity News article, please visit the following link: http://medcitynews.com/2014/11/israeli-white-blood-cell-based-wound-care-serum-headed-stateside/
The Physicians News Digest article, titled, "Innovation Could Spur Much-Needed Advances in Treating Diabetic Foot Ulcers," was written by Macrocure's President and CEO, Nissim Mashiach. He describes various approaches to treating Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs). To read the Physicians News Digest article, please visit the following link: www.physiciansnews.com/2014/12/02/innovation-could-spur-much-needed-advances-in-treating-diabetic-foot-ulcers/
The InformationAboutDiabetes article, titled, "CureXcell: Cell-Based Therapy as the Future in Wound Care," discusses why CureXcell stands out in the crowded market of advanced wound care products for diabetic foot ulcers (DFUs). A similar Q&A with Mr. Mashiach was published by Battle Diabetes.To read the InformationAboutDiabetes article, please visit the following link: www.informationaboutdiabetes.com/lifestyle/treatment/curexcell-cell-based-therapy-as-the-future-in-wound-care
To read the Battle Diabetes article, please visit the following link: http://www.battlediabetes.com/lifestyle/treatment/macrocures-curexcell-cell-based-therapy-for-severe-wound-care
In the Ostomy Wound Management article, Mr. Mashiach was selected as the month's "Industry Spotlight." The Q&A, published on December 9, profiles Mr. Mashiach and discusses recent accomplishments at Macrocure. To read the Ostomy Wound Management article, please visit the following link: http://www.o-wm.com/exclusives/industry-spotlight-nissim-mashiach-macrocure
The articles at the links above are provided for informational purposes only. Macrocure Ltd. is not responsible for the content of the linked articles.
About Macrocure Ltd.
Founded in 2008, Macrocure Ltd. is a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as DFUs and VLUs. The Company's novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body's own wound healing and regenerative components directly into the wound itself.
CONTACT: Francesca M. DeMartino Investor Relations & Corporate Communications Macrocure Ltd. (310) 739-6476 email@example.com